^
    Back
    Association details:
    Biomarker:HER-2 underexpression
    Cancer:Breast Cancer
    Drug:Kadcyla (ado-trastuzumab emtansine) (Microtubule inhibitor, HER2-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

    Excerpt:
    ...- HER2 low expression: 1+/2+ by immunohistochemistry and/or HER2/CEP17 ratio raception (barrier method [condoms, diaphragm] in conjunction with spermicidal jelly, or total abstinence....
    Trial ID:
    NATURE
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    1762 / 14 - A novel antibody drug conjugate linker enabling production of ADCs with high drug to antibody ratios and fast payload release for improved efficacy

    Published date:
    03/09/2022
    Excerpt:
    In a breast cancer model expressing low levels of Her2, a trastuzumab based multi-linker ADC with mertansine (DM1) at DAR8 showed superior activity, including complete tumor regressions, as compared to T-DM1 and T-Dxd and was well tolerated.
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2022
    Title:

    1787 / 16 - Statin therapy enhances the efficacy of HER2 directed antibody-drug conjugates in breast cancer

    Published date:
    03/09/2022
    Excerpt:
    ...lovastatin increased cell death caused by T-DM1 and sensitized the HER2-low ZR75-1 cells to T-DM1 treatment in vitro.
    Secondary therapy:
    lovastatin